On April 22, 2022, Joel Schneider, Chief Operating Officer of Solid Biosciences Inc., notified the company of his intent to resign to accept a role as chief executive officer of a privately-held novel, viral-based gene therapy platform company. Such resignation is expected to be effective as of May 27, 2022, after a period of transitioning his duties to internal successors.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.91 USD | -3.42% |
|
+34.75% | +28.83% |
Jul. 01 | Solid Biosciences Joins Russell 3000 Index | MT |
Jul. 01 | Solid Biosciences Inc.(NasdaqGS:SLDB) added to Russell Small Cap Comp Value Index | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+28.83% | 304M | |
+20.12% | 126B | |
+25.25% | 119B | |
+25.56% | 27.95B | |
-19.51% | 20.5B | |
-14.36% | 17.12B | |
-15.63% | 16.1B | |
-46.67% | 14.97B | |
+11.89% | 14.84B | |
+57.74% | 14.38B |
- Stock Market
- Equities
- SLDB Stock
- News Solid Biosciences Inc.
- Joel Schneider Intent to Resign as Chief Operating Officer of Solid Biosciences Inc., Effective May 27, 2022